MCID: PRT096
MIFTS: 42

Peritoneal Mesothelioma

Categories: Cancer diseases, Gastrointestinal diseases, Rare diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Peritoneal Mesothelioma

MalaCards integrated aliases for Peritoneal Mesothelioma:

Name: Peritoneal Mesothelioma 11 14 16 71 75
Malignant Mesothelioma of Peritoneum 11 71
Advanced Malignant Mesothelioma of Peritoneum 11
Advanced Malignant Peritoneal Mesothelioma 11
Advanced Peritoneal Malignant Mesothelioma 71

Classifications:



External Ids:

Disease Ontology 11 DOID:1788
NCIt 49 C8704 C9350
SNOMED-CT 68 187806007
ICD10 31 C45.1
UMLS 71 C0346109 C0854886 C1377610

Summaries for Peritoneal Mesothelioma

Disease Ontology: 11 A peritoneum cancer that develops from cells of the mesothelium and is located in the peritoneum.

MalaCards based summary: Peritoneal Mesothelioma, also known as malignant mesothelioma of peritoneum, is related to benign peritoneal mesothelioma and benign mesothelioma, and has symptoms including abdominal pain An important gene associated with Peritoneal Mesothelioma is CALB2 (Calbindin 2), and among its related pathways/superpathways is Malignant pleural mesothelioma. The drugs Doxorubicin and Ranpirnase have been mentioned in the context of this disorder. Affiliated tissues include peritoneum, ovary and pancreas, and related phenotype is neoplasm.

Wikipedia: 75 Peritoneal mesothelioma is the name given to the cancer that attacks the lining of the abdomen. This... more...

Related Diseases for Peritoneal Mesothelioma

Diseases in the Peritoneal Mesothelioma family:

Benign Peritoneal Mesothelioma Malignant Peritoneal Mesothelioma

Diseases related to Peritoneal Mesothelioma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 648)
# Related Disease Score Top Affiliating Genes
1 benign peritoneal mesothelioma 31.7 WT1 PTGER4 MSLN KRT7 KRT5 CEACAM5
2 benign mesothelioma 31.3 WT1 NF2 MTAP MSLN KRT7 KRT5
3 asbestosis 31.3 WT1 MSLN CALB2
4 tuberculous peritonitis 30.7 CEACAM5 CALB2
5 pseudomyxoma peritonei 30.6 TP53 KRT7 CEACAM5
6 hydrocele 30.5 WT1 KRT7 CALB2
7 mesothelioma, malignant 30.5 WT1 PTGER4 NF2 MSLN MIR625 KRT7
8 collecting duct carcinoma 30.4 SETD2 PAX8 KRT7
9 polycystic liver disease 1 with or without kidney cysts 30.4 KRT7 CEACAM5 CALB2
10 ocular melanoma 30.4 CDKN2A CD274 BAP1
11 ovarian serous carcinoma 30.3 WT1 TP53 PAX8
12 adenomatoid tumor 30.3 WT1 KRT7 KRT5 CALB2
13 cystadenoma 30.3 KRT7 CEACAM5 CALB2
14 malignant pleural mesothelioma 30.2 TP53 NF2 MSLN CDKN2A CD274 CALB2
15 serous cystadenocarcinoma 30.1 WT1 TP53 PAX8 KRT7 CDKN2A CALB2
16 malignant peripheral nerve sheath tumor 30.1 TP53 NF2 KRT7 CDKN2A
17 lymphangioma 30.1 TP53 KRT7 CEACAM5 CALB2
18 epithelial-myoepithelial carcinoma 30.0 KRT7 KRT5
19 verrucous carcinoma 30.0 TP53 KRT5 CDKN2A
20 gastrointestinal stromal tumor 30.0 TP53 NF2 CEACAM5 CDKN2A CD274
21 adenocarcinoma 29.9 TP53 KRT7 CEACAM5 CDKN2A CD274
22 melanoma, uveal 29.8 TP53 CDKN2A CD274 BAP1
23 appendix adenocarcinoma 29.8 TP53 PAX8 KRT7 CEACAM5
24 li-fraumeni syndrome 29.8 TP53 NF2 LUC7L2 CDKN2A
25 melanoma, cutaneous malignant 1 29.8 TP53 MTAP CDKN2A BAP1
26 rectal benign neoplasm 29.7 TP53 KRT7 CEACAM5
27 malignant epithelial mesothelioma 29.7 PTGER4 MSLN KRT7 CEACAM5 CALB2
28 dedifferentiated liposarcoma 29.7 TP53 CDKN2A CD274
29 ewing sarcoma 29.7 WT1 TP53 CDKN2A BAP1
30 papillary adenocarcinoma 29.7 TP53 PAX8 KRT7 KRT5 CEACAM5
31 liposarcoma 29.7 TP53 CDKN2A CD274 CALB2
32 lung squamous cell carcinoma 29.7 TP53 CEACAM5 CDKN2A CD274
33 malignant biphasic mesothelioma 29.6 WT1 MSLN KRT7 KRT5 CEACAM5 CALB2
34 mucinous adenocarcinoma 29.6 TP53 PAX8 KRT7 CEACAM5 CDKN2A
35 ovarian serous cystadenocarcinoma 29.6 TP53 PAX8 CEACAM5 CDKN2A
36 small cell cancer of the lung 29.6 TP53 KRT7 CEACAM5 CDKN2A
37 colonic benign neoplasm 29.6 TP53 KRT7 CEACAM5 CDKN2A
38 myelofibrosis 29.5 WT1 TP53 CDKN2A CD274
39 teratoma 29.5 TP53 KRT7 CEACAM5 CDKN2A CALB2
40 leukemia, acute lymphoblastic 29.5 WT1 TP53 SETD2 MTAP CDKN2A
41 lung cancer susceptibility 3 29.5 TP53 SETD2 MSLN KRT7 CEACAM5 CDKN2A
42 kidney cancer 29.4 WT1 TP53 SETD2 CDKN2A CD274
43 skin carcinoma 29.4 TP53 KRT7 KRT5 CDKN2A CD274
44 sarcomatoid mesothelioma 29.3 WT1 PTGER4 NF2 MTAP MSLN KRT5
45 ovary adenocarcinoma 29.3 WT1 TP53 PAX8 KRT7 CEACAM5 CDKN2A
46 peripheral nervous system disease 29.3 TP53 NF2 MIR380 CDKN2A CD274
47 lynch syndrome 29.2 TP53 KRT7 CEACAM5 CDKN2A CD274
48 pleural disease 29.2 TP53 NF2 MSLN MIR625 KRT5 CEACAM5
49 papillary serous adenocarcinoma 29.1 WT1 TP53 PTGER4 PAX8 KRT7 CEACAM5
50 pericardial mesothelioma 29.1 WT1 PTGER4 MSLN MIR1266 KRT7 KRT5

Graphical network of the top 20 diseases related to Peritoneal Mesothelioma:



Diseases related to Peritoneal Mesothelioma

Symptoms & Phenotypes for Peritoneal Mesothelioma

UMLS symptoms related to Peritoneal Mesothelioma:


abdominal pain

MGI Mouse Phenotypes related to Peritoneal Mesothelioma:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 neoplasm MP:0002006 9.23 BAP1 CDKN2A CEACAM5 NF2 PTGER4 SETD2

Drugs & Therapeutics for Peritoneal Mesothelioma

Drugs for Peritoneal Mesothelioma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 78)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
2
Ranpirnase Investigational Phase 3 196488-72-9
3 Liposomal doxorubicin Phase 3
4
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860
5
Durvalumab Approved, Investigational Phase 2 1428935-60-7
6
Gemcitabine Approved Phase 2 95058-81-4, 122111-03-9 60750
7
Erlotinib Approved, Investigational Phase 2 183319-69-9, 183321-74-6 176870
8
Celecoxib Approved, Investigational Phase 1, Phase 2 169590-42-5 2662
9
Atezolizumab Approved, Investigational Phase 2 1380723-44-3
10
Bevacizumab Approved, Investigational Phase 2 216974-75-3 135329020
11
Paclitaxel Approved, Vet_approved Phase 1, Phase 2 33069-62-4 36314
12
Nivolumab Approved Phase 2 946414-94-4
13
Ipilimumab Approved Phase 2 477202-00-9
14
Levoleucovorin Approved, Experimental, Investigational Phase 1, Phase 2 68538-85-2, 58-05-9, 73951-54-9 149436 6006
15
Cisplatin Approved Phase 1, Phase 2 15663-27-1 2767 5702198 441203
16
Pemetrexed Approved, Investigational Phase 1, Phase 2 150399-23-8, 137281-23-3 60843 446556 135565230
17
Carboplatin Approved Phase 1, Phase 2 41575-94-4 10339178 38904
18
Talazoparib Approved, Investigational Phase 2 1207456-01-6 135565082
19
Folic acid Approved, Nutraceutical, Vet_approved Phase 1, Phase 2 59-30-3 6037
20
Glutamic acid Approved, Nutraceutical Phase 1, Phase 2 56-86-0 33032
21
Tremelimumab Investigational Phase 2 745013-59-6
22 Interferon-gamma Phase 2
23 Antibiotics, Antitubercular Phase 2
24 Anti-Bacterial Agents Phase 2
25 Antiviral Agents Phase 2
26 Anti-Infective Agents Phase 2
27 Antimetabolites Phase 2
28 Immunosuppressive Agents Phase 2
29 Immunologic Factors Phase 2
30 Mitomycins Phase 2
31 Alkylating Agents Phase 2
32 Antirheumatic Agents Phase 1, Phase 2
33 interferons Phase 1, Phase 2
34 Protein Kinase Inhibitors Phase 2
35 Cyclooxygenase Inhibitors Phase 1, Phase 2
36 Cyclooxygenase 2 Inhibitors Phase 1, Phase 2
37 Interferon-alpha Phase 1, Phase 2
38 Interferon alpha-2 Phase 1, Phase 2
39 Vaccines Phase 1, Phase 2
40 Anti-Inflammatory Agents, Non-Steroidal Phase 1, Phase 2
41 Analgesics, Non-Narcotic Phase 1, Phase 2
42 poly(I).poly(c12,U) Phase 1, Phase 2
43 Anti-Inflammatory Agents Phase 1, Phase 2
44 Analgesics Phase 1, Phase 2
45 Antineoplastic Agents, Immunological Phase 2
46 Mitogens Phase 2
47 Angiogenesis Inhibitors Phase 2
48 Antibodies, Monoclonal Phase 2
49 Antibodies Phase 2
50 Endothelial Growth Factors Phase 2

Interventional clinical trials:

(show all 28)
# Name Status NCT ID Phase Drugs
1 ONCONASE Plus Doxorubicin Versus Doxorubicin For Patients With Malignant Pleural or Peritoneal Mesothelioma Who Have Had No More Than One Prior Chemotherapy Regimen Unknown status NCT00003034 Phase 3 doxorubicin hydrochloride;ranpirnase
2 Phase II Trial Of Combined Resection, Intraperitoneal Chemotherapy, And Whole Abdominal Radiation For Treatment Of Peritoneal Mesothelioma Unknown status NCT00024271 Phase 2 cisplatin;doxorubicin hydrochloride;gemcitabine hydrochloride;mitomycin C
3 A Two Stage, Open Label, Phase II Study of VELCADE Plus ELOXATIN in Previously Treated Patients With Malignant Pleural or Peritoneal Mesothelioma Unknown status NCT00996385 Phase 2 Velcade (bortezomib) plus Eloxatin (oxaliplatin)
4 A Single Arm, Phase II Clinical Study of Tremelimumab Combined With the Anti-PD-L1 MEDI4736 Monoclonal Antibody in Unresectable Malignant Mesothelioma Subjects: The NIBIT-MESO-1 Unknown status NCT02588131 Phase 2 tremelimumab plus MEDI4736
5 Oxaliplatin (Eloxatin®) Plus Gemcitabine as First or Second-line Chemotherapy for Patients With Malignant Pleural or Peritoneal Mesothelioma: A Phase II Clinical Trial Completed NCT00859469 Phase 2 Oxaliplatin;Gemcitabine
6 ALIMTA Plus Gemcitabine as Front-Line Chemotherapy for Patients With Malignant Pleural or Peritoneal Mesothelioma: A Phase II Clinical Trial Completed NCT00061477 Phase 2 Pemetrexed;Gemcitabine
7 Phase II Study of Erlotinib for Patients With Malignant Peritoneal Mesothelioma (MPeM) Exhibiting EGFR Mutations Completed NCT01592383 Phase 2 erlotinib hydrochloride
8 Phase II Study of IMC-A12 in Patients With Mesothelioma Who Have Been Previously Treated With Chemotherapy Completed NCT01160458 Phase 2 IMC-A12
9 Single Arm Study Treating Patients of Peritoneal Surface Malignancy (Colorectal, Appendical, Pseudomyxoma, Gastric) With Cytoreductive Surgery and Hyperthermic Intraperitoneal Mitomycin-C Completed NCT02040142 Phase 2 Mitomycin C
10 A Phase 1/2 Trial Evaluating αDC1 Vaccines Combined With Tumor-Selective Chemokine Modulation as Adjuvant Therapy After Surgical Resection of Peritoneal Surface Malignancies Completed NCT02151448 Phase 1, Phase 2 Celecoxib;Interferon Alfa-2b
11 Phase II Multicenter Randomized Trial Evaluating the Association of PIPAC and Systemic Chemotherapy Versus Systemic Chemotherapy Alone as 1st-line Treatment of Malignant Peritoneal Mesothelioma Recruiting NCT03875144 Phase 2 Cisplatin;Pemetrexed
12 Phase 2 Randomized Trial of Neoadjuvant or Palliative Chemotherapy With or Without Immunotherapy for Peritoneal Mesothelioma Recruiting NCT05001880 Phase 2 Carboplatin;Hyperthermic Intraperitoneal Chemotherapy;Pemetrexed
13 Intraperitoneal Paclitaxel for Patients With Primary Malignant Peritoneal Mesothelioma - a Phase I/II Dose Escalation and Safety Study Recruiting NCT05449366 Phase 1, Phase 2 Intraperitoneal Paclitaxel Solution (Ml)
14 A Phase II Prospective, Open-label Trial of Perioperative Combination Nivolumab and Ipilimumab in Patients With Resectable Malignant Peritoneal Mesothelioma Recruiting NCT05041062 Phase 2 Nivolumab;Ipilimumab
15 DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors Recruiting NCT02834013 Phase 2
16 A Phase II Clinical Trial to Evaluate Safety and Efficacy of XmAb20717 in Advanced Rare Cancers Recruiting NCT05337735 Phase 2 XmAb20717
17 Phase I Study of TRC102 in Combination With Cisplatin and Pemetrexed in Patients With Advanced Solid Tumors / Phase II Study of TRC102 With Pemetrexed in Patients Refractory to Pemetrexed and Cisplatin or Carboplatin Active, not recruiting NCT02535312 Phase 1, Phase 2 Cisplatin;Methoxyamine;Pemetrexed Disodium
18 A Three-Cohort Phase II Trial to Assess the Efficacy of a Maintenance Treatment With TALAzoparib Following First Line Platinum-based Chemotherapy in Pleural or Malignant Peritoneal MESOthelioma Patients Not yet recruiting NCT04462809 Phase 2 Talazoparib
19 Individualized Response Assessment to Heated Intraperitoneal Chemotherapy (HIPEC) for the Treatment of Peritoneal Carcinomatosis From Ovarian, Colorectal, Appendiceal, or Peritoneal Mesothelioma Histologies Recruiting NCT04847063 Phase 1 Mitomycin C;Cisplatin;Doxorubicin;Oxaliplatin;5-Fluorouracil;Sodium Thiosulfate
20 A Phase 1 Study of Intraperitoneal MCY-M11 Therapy for Women With Platinum Resistant High Grade Serous Adenocarcinoma of the Ovary, Primary Peritoneum, or Fallopian Tube, or Subjects With Peritoneal Mesothelioma With Recurrence After Prior Chemotherapy Terminated NCT03608618 Phase 1 Cyclophosphamide
21 A Phase I Study of the Mesothelin-Targeted Immunotoxin LMB-100 in Combination With SEL-110 in Subjects With Malignant Pleural or Peritoneal Mesothelioma Terminated NCT03436732 Phase 1 LMB-100;SEL-110
22 Phase 1 Study in Subjects With Tumors Requiring Arginine to Assess ADI-PEG 20 With Pemetrexed and Cisplatin (ADIPemCis) (TRAP Study) Terminated NCT02029690 Phase 1 ADI-PEG 20
23 French National Registry of Rare Peritoneal Surface Malignancies (RENAPE Registry) Unknown status NCT02834169
24 Genomic Analysis of Peritoneal Mesothelioma by CGH Arrays Completed NCT02834234
25 Survival of Peritoneal Mesothelioma After Cytoreductive Surgery and Hyperthermic Intra-peritoneal Chemotherapy (HIPEC) Completed NCT01812148
26 Magnetic Resonance Imaging for Detection of Peritoneal Mesothelioma Recruiting NCT03867578
27 Register With Data From Patients With the Diagnosis of a Peritoneal Surface Malignancy, for Which Cytoreductive Surgery and Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) is Performed Recruiting NCT01617382
28 Tissue Procurement for Gastric Cancer, Gastrointestinal Stromal Tumors (GIST), Esophageal Cancer, Pancreas Cancer, Hepatocellular Cancer, Biliary Cancer, Neuroendocrine, Peritoneal Mesothelioma, Anal Cancer and Colorectal Cancer in Patients Undergoing Surgery or Biopsy Suspended NCT01416714

Search NIH Clinical Center for Peritoneal Mesothelioma

Genetic Tests for Peritoneal Mesothelioma

Anatomical Context for Peritoneal Mesothelioma

Organs/tissues related to Peritoneal Mesothelioma:

FMA: Peritoneum
MalaCards : Ovary, Pancreas, Endothelial, Lymph Node, Lung, Liver, Small Intestine

Publications for Peritoneal Mesothelioma

Articles related to Peritoneal Mesothelioma:

(show top 50) (show all 1497)
# Title Authors PMID Year
1
FDG PET/CT for Staging and Restaging Malignant Mesothelioma. 62
35965111 2022
2
Co-Localization of Gastrointestinal Stromal Tumors (GIST) and Peritoneal Mesothelioma: A Case Series. 62
35849291 2022
3
ASO Visual Abstract: Co-localization of Gastrointestinal Stromal Tumors (GIST) and Peritoneal Mesothelioma: A Case Series. 62
36064993 2022
4
ASO Author Reflections: Co-Localization of Synchronous Gastrointestinal Stromal Tumors (GISTs) and Peritoneal Mesothelioma (PM): A Case Series. 62
35930107 2022
5
Analysis of malignant peritoneal mesothelioma treated by cryoablation combined with traditional Chinese medicine: A case report. 62
35781402 2022
6
Antibiotic administration via indwelling peritoneal catheter to treat infected malignant ascites. 62
36258693 2022
7
EWSR1::YY1 fusion positive peritoneal epithelioid mesothelioma harbors mesothelioma epigenetic signature: Report of 3 cases in support of an emerging entity. 62
35665561 2022
8
Malignant peritoneal mesothelioma with massive ascites as the first symptom: A case report. 62
36246798 2022
9
miR-550a-3p is a prognostic biomarker and exerts tumor-suppressive functions by targeting HSP90AA1 in diffuse malignant peritoneal mesothelioma. 62
35352023 2022
10
Safe performance of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with HIV infection. 62
35869601 2022
11
Localized Malignant Peritoneal Mesothelioma (LMPeM) in Women: A Clinicopathologic Study of 18 Cases. 62
35713639 2022
12
Genomic landscape of pleural and peritoneal mesothelioma tumours. 62
36138075 2022
13
Desmoid-type fibromatosis in the setting of malignant peritoneal mesothelioma: a case report of two rare diseases. 62
36171577 2022
14
Progression of Peritoneal Mesothelioma In Situ to Invasive Mesothelioma Arising in the Setting of Endometriosis With Germline BAP1 Mutation: A Case Report. 62
34723845 2022
15
Phase I Study of Tremelimumab Monotherapy or in Combination With Durvalumab in Japanese Patients With Advanced Solid Tumors or Malignant Mesothelioma. 62
35671201 2022
16
Expression of PD-L1 in Patients With Malignant Peritoneal Mesothelioma: A Pilot Study. 62
35489218 2022
17
Malignant Peritoneal Mesothelioma. 62
36245779 2022
18
Comprehensive Treatment Algorithms of the Swiss Peritoneal Cancer Group for Peritoneal Cancer of Gastrointestinal Origin. 62
36077810 2022
19
Clinical epidemiology of peritoneal metastases in China: The construction of professional peritoneal metastases treatment centers based on the prevalence rate. 62
36064631 2022
20
Malignant Peritoneal Mesothelioma: A Challenging Case for Palliative Care. 62
36059360 2022
21
Response to Ipilimumab and Nivolumab in a Patient With Malignant Peritoneal Mesothelioma. 62
36055919 2022
22
Malignant peritoneal mesothelioma. 62
35940275 2022
23
Bilateral Pleural Mesothelioma In Situ and Peritoneal Mesothelioma In Situ Associated With BAP1 Germline Mutation: A Case Report. 62
35814862 2022
24
Development of a Crosswalk to Translate Italian Occupation Codes to ISCO-68 Codes. 62
35211727 2022
25
Rare Histologies and Infrequent Indications for Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. 62
35790287 2022
26
Concurrent alcoholic cirrhosis and malignant peritoneal mesothelioma in a patient: A case report. 62
35979277 2022
27
Axillary lymph node metastasis as initial manifestation of malignant peritoneal mesothelioma; an unusual presentation. 62
35855720 2022
28
5-hmC loss is another useful tool in addition to BAP1 and MTAP immunostains to distinguish diffuse malignant peritoneal mesothelioma from reactive mesothelial hyperplasia in peritoneal cytology cell-blocks and biopsies. 62
35575935 2022
29
Malignant Peritoneal Mesothelioma Presenting with High Protein, High Serum-Ascites Albumin Gradient. 62
36039211 2022
30
Nivolumab for pediatric malignant peritoneal mesothelioma. 62
35851543 2022
31
Intraperitoneal paclitaxel for patients with primary malignant peritoneal mesothelioma: a phase I/II dose escalation and safety study-INTERACT MESO. 62
35732399 2022
32
Peritoneal mesothelioma presenting with 'kissing' liver metastases. 62
34860121 2022
33
Prognostic factors of malignant peritoneal mesothelioma: a retrospective study of 52 female patients. 62
35765009 2022
34
Clinical-pathological characteristics and prognostic factors for malignant peritoneal mesothelioma in the elderly. 62
35681152 2022
35
Ten-year single-center experience with treatment of primary diffuse malignant peritoneal mesothelioma (DMPM) by cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). 62
35732846 2022
36
Cytoreductive Surgery and HIPEC for Malignant Peritoneal Mesothelioma: Outcomes and Survival From an Australian Centre. 62
35641285 2022
37
Ultra-high drug loading improves nanoparticle efficacy against peritoneal mesothelioma. 62
35487067 2022
38
Malignant peritoneal mesothelioma literature review: past, present, and future. 62
36061260 2022
39
Substance GP-2250 as a New Therapeutic Agent for Malignant Peritoneal Mesothelioma-A 3-D In Vitro Study. 62
35806313 2022
40
Asbestos danger in central Europe is not yet over - the situation in the Czech Republic. 62
35876593 2022
41
Molecular Characterization of Mesothelioma: Impact of Histologic Type and Site of Origin on Molecular Landscape. 62
35704798 2022
42
Hepatic bridge and round ligament of the liver during cytoreductive surgery: a retrospective cohort. 62
34845541 2022
43
The role of imaging in diagnosis and management of malignant peritoneal mesothelioma: a systematic review. 62
35257201 2022
44
BAP1 and Claudin-4, But Not MTAP, Reliably Distinguish Borderline and Low-grade Serous Ovarian Tumors From Peritoneal Mesothelioma. 62
35512220 2022
45
Benign Multicystic Peritoneal Mesothelioma Complicating Fertility Preservation. 62
35746905 2022
46
Primary malignant peritoneal mesothelioma mimicking tuberculous peritonitis: A case report. 62
35647134 2022
47
CT imaging of malignant peritoneal mesothelioma: A case report. 62
35198088 2022
48
NPM2 in malignant peritoneal mesothelioma: from basic tumor biology to clinical medicine. 62
35490253 2022
49
Non-resectable Malignant Peritoneal Mesothelioma Treated with Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Plus Systemic Chemotherapy Could Lead to Secondary Complete Cytoreductive Surgery: A Cohort Study. 62
34713369 2022
50
ASO Visual Abstract: Non-resectable Malignant Peritoneal Mesothelioma Treated with Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Plus Systemic Chemotherapy Could Lead to Secondary Complete Cytoreductive Surgery: A Cohort Study. 62
34845568 2022

Variations for Peritoneal Mesothelioma

Expression for Peritoneal Mesothelioma

Search GEO for disease gene expression data for Peritoneal Mesothelioma.

Pathways for Peritoneal Mesothelioma

Pathways related to Peritoneal Mesothelioma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.71 TP53 SETD2 NF2 CDKN2A CD274 BAP1

GO Terms for Peritoneal Mesothelioma

Biological processes related to Peritoneal Mesothelioma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cellular response to gonadotropin stimulus GO:0071371 9.56 WT1 PAX8
2 metanephric S-shaped body morphogenesis GO:0072284 9.46 WT1 PAX8
3 negative regulation of cell population proliferation GO:0008285 9.4 WT1 TP53 STRN NF2 CDKN2A BAP1
4 metanephric epithelium development GO:0072207 9.26 WT1 PAX8

Sources for Peritoneal Mesothelioma

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 24-Oct-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....